SH
SHINIL PHARMACEUTICAL CO., LTD.
012790 | KO
Overview
Corporate Details
- ISIN(s):
- KR7012790002
- LEI:
- Country:
- South Korea
- Address:
- 충북 충주시 앙성면 본평리 산 5-1, 충주시
- Website:
- https://shinilpharma.com/
- Sector:
- Manufacturing
- Industry:
- Manufacture of pharmaceuticals, medicinal chemical and botanical products
Description
No description available.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
You have of free filing views remaining.
Upgrade for unlimited access.
Bulk Actions:
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2025-09-05 00:00 |
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
|
Korean | 25.1 KB | ||
| 2025-08-14 00:00 |
Interim / Quarterly Report
반기보고서 (2025.06)
|
Korean | 841.2 KB | ||
| 2025-05-15 00:00 |
Quarterly Report
분기보고서 (2025.03)
|
Korean | 876.9 KB | ||
| 2025-03-24 00:00 |
AGM Information
정기주주총회결과
|
Korean | 22.2 KB | ||
| 2025-03-14 00:00 |
Audit Report / Information
감사보고서제출
|
Korean | 17.2 KB | ||
| 2025-03-14 00:00 |
Annual Report
사업보고서 (2024.12)
|
Korean | 1.0 MB | ||
| 2025-03-07 00:00 |
Pre-Annual General Meeting Information
주주총회소집결의
|
Korean | 10.8 KB | ||
| 2025-03-07 00:00 |
Pre-Annual General Meeting Information
주주총회소집공고
|
Korean | 87.0 KB | ||
| 2025-03-04 00:00 |
Notice of Dividend Amount
현금ㆍ현물배당결정
|
Korean | 9.3 KB | ||
| 2024-12-16 00:00 |
Pre-Annual General Meeting Information
주주명부폐쇄기간또는기준일설정
|
Korean | 4.3 KB | ||
| 2024-12-16 00:00 |
Notice of Dividend Amount
현금ㆍ현물배당을위한주주명부폐쇄(기준일)결정
|
Korean | 5.6 KB | ||
| 2024-11-14 00:00 |
Quarterly Report
분기보고서 (2024.09)
|
Korean | 740.8 KB | ||
| 2024-08-09 00:00 |
Interim / Quarterly Report
반기보고서 (2024.06)
|
Korean | 738.9 KB | ||
| 2024-06-05 00:00 |
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
|
Korean | 20.9 KB | ||
| 2024-05-16 00:00 |
Quarterly Report
분기보고서 (2024.03)
|
Korean | 788.8 KB |
Automate Your Workflow. Get a real-time feed of all SHINIL PHARMACEUTICAL CO., LTD. filings delivered via API.
Market Data
Market Data Not Available
Last Price
Change / %
Market Cap
N/A
Volume
Day High
Day Low
52W High
52W Low
Financials & KPIs
No data available
Unlock Full Financials for SHINIL PHARMACEUTICAL CO., LTD.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for SHINIL PHARMACEUTICAL CO., LTD. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
Company
Country
Ticker
View
Developing precision small molecule therapies for cancers, autoimmune, and rare diseases.
United States of America
COGT
United States of America
COGT
Commercial-stage biopharma developing immuno-oncology therapies for hard-to-treat cancers.
United States of America
CHRS
United States of America
CHRS
Develops and commercializes abuse-deterrent medications for responsible chronic pain management.
United States of America
COLL
United States of America
COLL
Develops rhCollagen for 3D bioprinting of tissues for regenerative & aesthetic medicine.
United States of America
CLGN
United States of America
CLGN
Developing psilocybin therapies for severe mental health challenges like TRD and PTSD.
United States of America
CMPS
United States of America
CMPS
A clinical-stage oncology firm developing antibody therapies that engage the immune system.
United States of America
CMPX
United States of America
CMPX
Develops immune modulators for T cell-driven inflammatory diseases like asthma and COPD.
United States of America
CNTB
United States of America
CNTB
Clinical-stage biopharma developing T cell engaging bispecific antibodies for solid tumors.
United States of America
CNTX
United States of America
CNTX
Develops oral small molecule therapies for neurological, inflammatory, and fibrotic diseases.
United States of America
CTNM
United States of America
CTNM
Clinical-stage oncology company developing targeted therapies like ADCs for cancer and obesity.
United States of America
CRBP
United States of America
CRBP